Tradestie Institutional Equity Comparison Engine

DAWN vs BCAX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

DAWN Overall Edge

DAWN Captures Institutional Edge (2โ€“1 Pillars ยท 6โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Day One Biopharmaceuticals, Inc. Common Stock (DAWN) driven by superior Momentum & Technical, Options & Structure while BCAX counters with relative strength in Growth & Margin. Fundamentally, DAWN trades at N/M Forward P/E with -51.1% operating margin (+83.9% YoY revenue) versus BCAX at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, DAWN sits in UNCLASSIFIED (<1st %ile IV; Dealer Gamma Walls on Pro) against BCAX sits in BREAKDOWN (23rd %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
DAWN N/M vs BCAX N/M Fwd P/E
Growth & Margin Winner BCAX
Op Margin -51.1% vs 0.0% ยท YoY +83.9% vs +0.0%
Momentum & Technical Winner DAWN
1Y +201.5% vs -31.6% ยท 52W Pos 100% vs 8%
Options & Structure Winner DAWN
UNCLASSIFIED (<1st %ile IV) vs BREAKDOWN (23rd %ile IV)
DAWN NASDAQ
Day One Biopharmaceuticals, Inc. Common Stock
Pharmaceutical Preparations
$21.53
+0.19% 1D
Market Cap $2.2B
1M Return +0.8%
1Y Return +201.54%
Forward P/E N/M
Unified AI Score
58.3 / 100 HOLD
Tech 40.0 Fund 50.0 Flow 66.0 Mom 46.0
BCAX NASDAQ
Bicara Therapeutics Inc. Common Stock
Pharmaceutical Preparations
$9.75
-2.69% 1D
Market Cap $665.2M
1M Return -41.9%
1Y Return -31.63%
Forward P/E N/M
Unified AI Score
52.1 / 100 HOLD
Tech 58.0 Fund 66.0 Flow 68.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DAWN +201.54% BCAX -31.63% Spread: +77.57 pp (DAWN Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
DAWN TTM Op. Margin: -51.1% BCAX TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DAWN vs BCAX. Trailing 12-month operating profitability (DAWN -51.1% vs BCAX 0.0%) and valuation multiples (DAWN N/M vs BCAX N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DAWN (6) vs BCAX (2)
Institutional Metric DAWN BCAX Criterion Row Winner
Market Capitalization Scale $2.2B $665.2M Larger Scale DAWN
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth +83.9% +0.0% Higher Growth DAWN
Operating Margin (TTM) Profitability -51.1% 0.0% Higher Margin BCAX
Net Profit Margin Profitability -67.8% 0.0% Higher Margin BCAX
Return on Equity (ROE) Capital Efficiency -22.7% -54.2% Higher ROE DAWN
52-Week Range Position Momentum 100% ($6โ€“$22) 8% ($8โ€“$31) Stronger Trend DAWN
Beta / 30D Volatility Risk Regime 0.03ฮฒ ยท 2% Vol 1.42ฮฒ ยท 184% Vol Lower Realized Risk DAWN
Unified Institutional Score Composite Signal 58.3 / 100 (HOLD) 52.1 / 100 (HOLD) Higher Composite DAWN

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DAWN vs BCAX Buy Guide
DAWN UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile <1st %ile
IV Regime Compressed (<25th %ile)
Live DAWN Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
BCAX BREAKDOWN
93d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 23rd %ile
IV Regime Compressed (<25th %ile)
Live BCAX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DAWN nor BCAX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.